FDA sheds light on criteria for approving PAIs based on remote inspections
Regulatory NewsJoanne S. Eglovitch
Audit/inspectionBiologics/ biosimilars/ vaccinesComplianceNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyRegulatory NewsJoanne S. EglovitchAudit/inspectionBiologics/ biosimilars/ vaccinesComplianceNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy